KR100832747B1 - 아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물 - Google Patents
아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물 Download PDFInfo
- Publication number
- KR100832747B1 KR100832747B1 KR1020060105183A KR20060105183A KR100832747B1 KR 100832747 B1 KR100832747 B1 KR 100832747B1 KR 1020060105183 A KR1020060105183 A KR 1020060105183A KR 20060105183 A KR20060105183 A KR 20060105183A KR 100832747 B1 KR100832747 B1 KR 100832747B1
- Authority
- KR
- South Korea
- Prior art keywords
- pyrazole
- phenethyl
- carboxylic acid
- acetylamino
- methyl ester
- Prior art date
Links
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical class NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 208000023589 ischemic disease Diseases 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title abstract description 93
- 230000000302 ischemic effect Effects 0.000 claims abstract description 24
- 230000030833 cell death Effects 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 230000001404 mediated effect Effects 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 181
- -1 4-Bromo-phenylsulfanyl Chemical group 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 206010008118 cerebral infarction Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 230000007774 longterm Effects 0.000 claims description 6
- 208000031225 myocardial ischemia Diseases 0.000 claims description 6
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 5
- 201000006474 Brain Ischemia Diseases 0.000 claims description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 5
- 206010009895 Colitis ischaemic Diseases 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 208000033626 Renal failure acute Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 201000011040 acute kidney failure Diseases 0.000 claims description 5
- 208000012998 acute renal failure Diseases 0.000 claims description 5
- 201000008222 ischemic colitis Diseases 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 206010050081 Neonatal hypoxia Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000019622 heart disease Diseases 0.000 claims description 4
- 208000032253 retinal ischemia Diseases 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- ZDSJSGYWTUXEIR-UHFFFAOYSA-N 2-(4-bromophenyl)sulfanyl-N-[3-(hydroxymethyl)-1-(1-phenylethyl)pyrazol-4-yl]acetamide Chemical compound BrC1=CC=C(C=C1)SCC(=O)NC=1C(=NN(C1)C(C)C1=CC=CC=C1)CO ZDSJSGYWTUXEIR-UHFFFAOYSA-N 0.000 claims description 3
- LABMPMHDWFCTCV-UHFFFAOYSA-N 2-(4-bromophenyl)sulfanyl-N-[3-(methoxymethyl)-1-(1-phenylethyl)pyrazol-4-yl]acetamide Chemical compound BrC1=CC=C(C=C1)SCC(=O)NC=1C(=NN(C=1)C(C)C1=CC=CC=C1)COC LABMPMHDWFCTCV-UHFFFAOYSA-N 0.000 claims description 3
- SEKSVXONADAZTC-UHFFFAOYSA-N 4-[[2-(4-bromophenyl)sulfanylacetyl]amino]-1-(2-phenylethyl)pyrazole-3-carboxamide Chemical compound C1=C(NC(=O)CSC=2C=CC(Br)=CC=2)C(C(=O)N)=NN1CCC1=CC=CC=C1 SEKSVXONADAZTC-UHFFFAOYSA-N 0.000 claims description 3
- ZRLJEHIUGYTTSZ-UHFFFAOYSA-N 4-[[2-(4-bromophenyl)sulfanylacetyl]amino]-1-(2-phenylethyl)pyrazole-3-carboxylic acid Chemical compound C1=C(NC(=O)CSC=2C=CC(Br)=CC=2)C(C(=O)O)=NN1CCC1=CC=CC=C1 ZRLJEHIUGYTTSZ-UHFFFAOYSA-N 0.000 claims description 3
- UQZWVFXWQLJXAC-UHFFFAOYSA-N COC(=O)C1=NN(C=C1NC(CSC1=CC=C(C=C1)F)=O)C(C)C1=CC=CC=C1 Chemical compound COC(=O)C1=NN(C=C1NC(CSC1=CC=C(C=C1)F)=O)C(C)C1=CC=CC=C1 UQZWVFXWQLJXAC-UHFFFAOYSA-N 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 3
- VUTISDDFOKZULS-UHFFFAOYSA-N ethyl 5-[[2-(4-bromophenyl)sulfanylacetyl]amino]-1-(1-phenylethyl)pyrazole-4-carboxylate Chemical compound C(C)OC(=O)C=1C=NN(C=1NC(CSC1=CC=C(C=C1)Br)=O)C(C)C1=CC=CC=C1 VUTISDDFOKZULS-UHFFFAOYSA-N 0.000 claims description 3
- MRYRYMAXPOJTNL-UHFFFAOYSA-N methyl 1-(1-phenylethyl)-4-(3-phenylpropanoylamino)pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1NC(CCC1=CC=CC=C1)=O)C(C)C1=CC=CC=C1 MRYRYMAXPOJTNL-UHFFFAOYSA-N 0.000 claims description 3
- YBMUIXQZYAHVGG-UHFFFAOYSA-N methyl 1-(1-phenylethyl)-4-[(2-phenylsulfanylacetyl)amino]pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1NC(CSC1=CC=CC=C1)=O)C(C)C1=CC=CC=C1 YBMUIXQZYAHVGG-UHFFFAOYSA-N 0.000 claims description 3
- XVHSDTXJGQLGFU-UHFFFAOYSA-N methyl 1-(1-phenylethyl)-4-[(2-pyridin-2-ylsulfanylacetyl)amino]pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1NC(CSC1=NC=CC=C1)=O)C(C)C1=CC=CC=C1 XVHSDTXJGQLGFU-UHFFFAOYSA-N 0.000 claims description 3
- LGZUOGHDPRMTDV-UHFFFAOYSA-N methyl 1-(1-phenylethyl)-4-[(2-pyridin-2-ylsulfinylacetyl)amino]pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1NC(CS(=O)C1=NC=CC=C1)=O)C(C)C1=CC=CC=C1 LGZUOGHDPRMTDV-UHFFFAOYSA-N 0.000 claims description 3
- JZEXZRPBQLXMEC-UHFFFAOYSA-N methyl 1-(1-phenylethyl)-4-[(2-pyridin-2-ylsulfonylacetyl)amino]pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1NC(CS(=O)(=O)C1=NC=CC=C1)=O)C(C)C1=CC=CC=C1 JZEXZRPBQLXMEC-UHFFFAOYSA-N 0.000 claims description 3
- QUFDJAMXLQKHAH-UHFFFAOYSA-N methyl 4-[[2-(2-aminophenyl)sulfanylacetyl]amino]-1-(1-phenylethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1NC(CSC1=C(C=CC=C1)N)=O)C(C)C1=CC=CC=C1 QUFDJAMXLQKHAH-UHFFFAOYSA-N 0.000 claims description 3
- YOLDKCJJJMDMKA-UHFFFAOYSA-N methyl 4-[[2-(3,4-dimethylphenyl)sulfanylacetyl]amino]-1-(1-phenylethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1NC(CSC1=CC(=C(C=C1)C)C)=O)C(C)C1=CC=CC=C1 YOLDKCJJJMDMKA-UHFFFAOYSA-N 0.000 claims description 3
- CMNUJUWKDXNZGY-UHFFFAOYSA-N methyl 4-[[2-(3-methoxyphenyl)sulfanylacetyl]amino]-1-(1-phenylethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1NC(CSC1=CC(=CC=C1)OC)=O)C(C)C1=CC=CC=C1 CMNUJUWKDXNZGY-UHFFFAOYSA-N 0.000 claims description 3
- GEZZCYROQOJTPE-UHFFFAOYSA-N methyl 4-[[2-(4-bromoanilino)acetyl]amino]-1-(1-phenylethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1NC(CNC1=CC=C(C=C1)Br)=O)C(C)C1=CC=CC=C1 GEZZCYROQOJTPE-UHFFFAOYSA-N 0.000 claims description 3
- OIWFIYCGCHYHKL-UHFFFAOYSA-N methyl 4-[[2-(4-bromophenoxy)acetyl]amino]-1-(1-phenylethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1NC(COC1=CC=C(C=C1)Br)=O)C(C)C1=CC=CC=C1 OIWFIYCGCHYHKL-UHFFFAOYSA-N 0.000 claims description 3
- ZSWGXRRYRNDEIU-UHFFFAOYSA-N methyl 4-[[2-(4-bromophenyl)sulfanyl-2-phenylacetyl]amino]-1-(1-phenylethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1NC(C(C1=CC=CC=C1)SC1=CC=C(C=C1)Br)=O)C(C)C1=CC=CC=C1 ZSWGXRRYRNDEIU-UHFFFAOYSA-N 0.000 claims description 3
- RJQWQPGFNKKGMK-UHFFFAOYSA-N methyl 4-[[2-(4-bromophenyl)sulfanylacetyl]amino]-1-(2-phenylethyl)pyrazole-3-carboxylate Chemical compound C1=C(NC(=O)CSC=2C=CC(Br)=CC=2)C(C(=O)OC)=NN1CCC1=CC=CC=C1 RJQWQPGFNKKGMK-UHFFFAOYSA-N 0.000 claims description 3
- JYYVKRBENBOFNN-UHFFFAOYSA-N methyl 4-[[2-(4-bromophenyl)sulfanylacetyl]amino]-2-(2-phenylethyl)pyrazole-3-carboxylate Chemical compound C1=NN(CCC=2C=CC=CC=2)C(C(=O)OC)=C1NC(=O)CSC1=CC=C(Br)C=C1 JYYVKRBENBOFNN-UHFFFAOYSA-N 0.000 claims description 3
- GGXOGHVJCRLYRH-UHFFFAOYSA-N methyl 4-[[2-(4-methylphenyl)sulfanylacetyl]amino]-1-(1-phenylethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1NC(CSC1=CC=C(C=C1)C)=O)C(C)C1=CC=CC=C1 GGXOGHVJCRLYRH-UHFFFAOYSA-N 0.000 claims description 3
- IAFKACVQYLSOGU-UHFFFAOYSA-N methyl 4-[[2-(4-nitrophenyl)sulfanylacetyl]amino]-1-(1-phenylethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1NC(CSC1=CC=C(C=C1)[N+](=O)[O-])=O)C(C)C1=CC=CC=C1 IAFKACVQYLSOGU-UHFFFAOYSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 claims 1
- 229940047583 cetamide Drugs 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 4
- 210000000056 organ Anatomy 0.000 abstract description 4
- 230000000069 prophylactic effect Effects 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 239000011814 protection agent Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 297
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 147
- 230000002829 reductive effect Effects 0.000 description 110
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 99
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 85
- 239000002904 solvent Substances 0.000 description 74
- 238000005481 NMR spectroscopy Methods 0.000 description 58
- 239000003960 organic solvent Substances 0.000 description 53
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 52
- 239000011541 reaction mixture Substances 0.000 description 52
- 239000012267 brine Substances 0.000 description 51
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 51
- 239000012299 nitrogen atmosphere Substances 0.000 description 50
- 238000004440 column chromatography Methods 0.000 description 49
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 229940086542 triethylamine Drugs 0.000 description 33
- 238000004519 manufacturing process Methods 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 239000002585 base Substances 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000003756 stirring Methods 0.000 description 14
- 208000028867 ischemia Diseases 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 12
- FTBCOQFMQSTCQQ-UHFFFAOYSA-N 4-bromobenzenethiol Chemical compound SC1=CC=C(Br)C=C1 FTBCOQFMQSTCQQ-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 238000009835 boiling Methods 0.000 description 9
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 239000007810 chemical reaction solvent Substances 0.000 description 5
- ARAFBUCGMOKZMI-UHFFFAOYSA-N methyl 4-nitro-1h-pyrazole-5-carboxylate Chemical compound COC(=O)C=1NN=CC=1[N+]([O-])=O ARAFBUCGMOKZMI-UHFFFAOYSA-N 0.000 description 5
- 230000010410 reperfusion Effects 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 4
- 238000010640 amide synthesis reaction Methods 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 3
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 125000005999 2-bromoethyl group Chemical group 0.000 description 2
- BXVSAYBZSGIURM-UHFFFAOYSA-N 2-phenoxy-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide Chemical compound O1CC2=CC=CC=C2OP1(=O)OC1=CC=CC=C1 BXVSAYBZSGIURM-UHFFFAOYSA-N 0.000 description 2
- KLAJWESPWMZKQL-UHFFFAOYSA-N 3-(methoxymethyl)-4-nitro-1-(1-phenylethyl)pyrazole Chemical compound C1=C([N+]([O-])=O)C(COC)=NN1C(C)C1=CC=CC=C1 KLAJWESPWMZKQL-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010029333 Neurosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000004210 ether based solvent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000004820 halides Chemical group 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- BDKRMDQJVSUCAR-UHFFFAOYSA-N methyl 1-benzyl-4-[(2-phenylsulfanylacetyl)amino]pyrazole-3-carboxylate Chemical compound C1=C(NC(=O)CSC=2C=CC=CC=2)C(C(=O)OC)=NN1CC1=CC=CC=C1 BDKRMDQJVSUCAR-UHFFFAOYSA-N 0.000 description 2
- FTJLWNBBYQIPHY-UHFFFAOYSA-N methyl 1-benzyl-4-[[2-(4-bromophenyl)sulfanylacetyl]amino]pyrazole-3-carboxylate Chemical compound C1=C(NC(=O)CSC=2C=CC(Br)=CC=2)C(C(=O)OC)=NN1CC1=CC=CC=C1 FTJLWNBBYQIPHY-UHFFFAOYSA-N 0.000 description 2
- ZRIFCWIEIFPSLY-UHFFFAOYSA-N methyl 1-methyl-4-[(2-phenylsulfanylacetyl)amino]pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C)C=C1NC(=O)CSC1=CC=CC=C1 ZRIFCWIEIFPSLY-UHFFFAOYSA-N 0.000 description 2
- AXSGGAACEODKAL-UHFFFAOYSA-N methyl 1-methyl-5-[(2-phenylsulfanylacetyl)amino]pyrazole-3-carboxylate Chemical compound CN1N=C(C(=O)OC)C=C1NC(=O)CSC1=CC=CC=C1 AXSGGAACEODKAL-UHFFFAOYSA-N 0.000 description 2
- KIQQHCGJSMLRNE-UHFFFAOYSA-N methyl 4-[[2-(4-bromophenyl)sulfanylacetyl]amino]-1-methylpyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C)C=C1NC(=O)CSC1=CC=C(Br)C=C1 KIQQHCGJSMLRNE-UHFFFAOYSA-N 0.000 description 2
- LKAFRKZMVVVQOT-UHFFFAOYSA-N methyl 4-[[2-(4-bromophenyl)sulfanylacetyl]amino]-2-methylpyrazole-3-carboxylate Chemical compound C1=NN(C)C(C(=O)OC)=C1NC(=O)CSC1=CC=C(Br)C=C1 LKAFRKZMVVVQOT-UHFFFAOYSA-N 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- DWXSYDKEWORWBT-UHFFFAOYSA-N 2-(2-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1Br DWXSYDKEWORWBT-UHFFFAOYSA-N 0.000 description 1
- IXAKNMVAKISGTI-UHFFFAOYSA-N 2-(4-bromophenyl)sulfanyl-n-[3-(4,5-dihydro-1,3-oxazol-2-yl)-1-(2-phenylethyl)pyrazol-4-yl]acetamide Chemical compound C1=CC(Br)=CC=C1SCC(=O)NC(C(=N1)C=2OCCN=2)=CN1CCC1=CC=CC=C1 IXAKNMVAKISGTI-UHFFFAOYSA-N 0.000 description 1
- VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical compound NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 1
- OPYALRVJVXWILN-UHFFFAOYSA-N 2-bromo-N-[3-(methoxymethyl)-1-(1-phenylethyl)pyrazol-4-yl]acetamide Chemical compound C1=C(NC(=O)CBr)C(COC)=NN1C(C)C1=CC=CC=C1 OPYALRVJVXWILN-UHFFFAOYSA-N 0.000 description 1
- VOBIHUAWDXUCPH-UHFFFAOYSA-N 2-chloro-5,5-dimethylcyclohexane-1,3-dione Chemical compound CC1(C)CC(=O)C(Cl)C(=O)C1 VOBIHUAWDXUCPH-UHFFFAOYSA-N 0.000 description 1
- VKPPFDPXZWFDFA-UHFFFAOYSA-N 2-chloroethanamine Chemical compound NCCCl VKPPFDPXZWFDFA-UHFFFAOYSA-N 0.000 description 1
- ONRREFWJTRBDRA-UHFFFAOYSA-N 2-chloroethanamine;hydron;chloride Chemical compound [Cl-].[NH3+]CCCl ONRREFWJTRBDRA-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- IDKCKPBAFOIONK-UHFFFAOYSA-N 3,4-dimethylbenzenethiol Chemical compound CC1=CC=C(S)C=C1C IDKCKPBAFOIONK-UHFFFAOYSA-N 0.000 description 1
- DHXNZYCXMFBMHE-UHFFFAOYSA-N 3-bromopropanoic acid Chemical compound OC(=O)CCBr DHXNZYCXMFBMHE-UHFFFAOYSA-N 0.000 description 1
- QMVAZEHZOPDGHA-UHFFFAOYSA-N 3-methoxybenzenethiol Chemical compound COC1=CC=CC(S)=C1 QMVAZEHZOPDGHA-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- OKIHXNKYYGUVTE-UHFFFAOYSA-N 4-Fluorothiophenol Chemical compound FC1=CC=C(S)C=C1 OKIHXNKYYGUVTE-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- WLHCBQAPPJAULW-UHFFFAOYSA-N 4-methylbenzenethiol Chemical compound CC1=CC=C(S)C=C1 WLHCBQAPPJAULW-UHFFFAOYSA-N 0.000 description 1
- AXBVSRMHOPMXBA-UHFFFAOYSA-N 4-nitrothiophenol Chemical compound [O-][N+](=O)C1=CC=C(S)C=C1 AXBVSRMHOPMXBA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VSNKOCWXSAAATM-UHFFFAOYSA-N C1=C([N+]([O-])=O)C(CO)=NN1C(C)C1=CC=CC=C1 Chemical compound C1=C([N+]([O-])=O)C(CO)=NN1C(C)C1=CC=CC=C1 VSNKOCWXSAAATM-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- XWUZGNUDWBCPHB-UHFFFAOYSA-N NC1=C(C=NN1C(C)C1=CC=CC=C1)C(=O)OCC Chemical compound NC1=C(C=NN1C(C)C1=CC=CC=C1)C(=O)OCC XWUZGNUDWBCPHB-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 229940045200 cardioprotective agent Drugs 0.000 description 1
- 239000012659 cardioprotective agent Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- GCSAXWHQFYOIFE-UHFFFAOYSA-N dipyridin-2-yl carbonate Chemical compound C=1C=CC=NC=1OC(=O)OC1=CC=CC=N1 GCSAXWHQFYOIFE-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- YPXGHKWOJXQLQU-UHFFFAOYSA-N ethyl 5-amino-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1N YPXGHKWOJXQLQU-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WYJPBGPANHUKEO-UHFFFAOYSA-N methyl 1-benzyl-4-[(2-bromoacetyl)amino]pyrazole-3-carboxylate Chemical compound C1=C(NC(=O)CBr)C(C(=O)OC)=NN1CC1=CC=CC=C1 WYJPBGPANHUKEO-UHFFFAOYSA-N 0.000 description 1
- HTDPPRRYQBHSFB-UHFFFAOYSA-N methyl 1-benzyl-4-nitropyrazole-3-carboxylate Chemical compound C1=C([N+]([O-])=O)C(C(=O)OC)=NN1CC1=CC=CC=C1 HTDPPRRYQBHSFB-UHFFFAOYSA-N 0.000 description 1
- KRIOGKNOYPHJPC-UHFFFAOYSA-N methyl 1-methyl-4-nitropyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C)C=C1[N+]([O-])=O KRIOGKNOYPHJPC-UHFFFAOYSA-N 0.000 description 1
- FZEMXZUQMMIYQY-UHFFFAOYSA-N methyl 1-methyl-5-nitropyrazole-3-carboxylate Chemical compound COC(=O)C=1C=C([N+]([O-])=O)N(C)N=1 FZEMXZUQMMIYQY-UHFFFAOYSA-N 0.000 description 1
- ANWHCLPGJQUYRX-UHFFFAOYSA-N methyl 2-methyl-4-nitropyrazole-3-carboxylate Chemical compound COC(=O)C1=C([N+]([O-])=O)C=NN1C ANWHCLPGJQUYRX-UHFFFAOYSA-N 0.000 description 1
- MDMGTKBZTFRZEP-UHFFFAOYSA-N methyl 4-(3-bromopropanoylamino)-1-(1-phenylethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1NC(CCBr)=O)C(C)C1=CC=CC=C1 MDMGTKBZTFRZEP-UHFFFAOYSA-N 0.000 description 1
- HXDUEHBMYKOMDI-UHFFFAOYSA-N methyl 4-[(2-bromo-2-phenylacetyl)amino]-1-(1-phenylethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1NC(C(C1=CC=CC=C1)Br)=O)C(C)C1=CC=CC=C1 HXDUEHBMYKOMDI-UHFFFAOYSA-N 0.000 description 1
- FUSLSOODOJXUKM-UHFFFAOYSA-N methyl 4-[(2-bromoacetyl)amino]-1-(1-phenylethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1NC(CBr)=O)C(C)C1=CC=CC=C1 FUSLSOODOJXUKM-UHFFFAOYSA-N 0.000 description 1
- QISBIOBFYGPHSW-UHFFFAOYSA-N methyl 4-[(2-bromoacetyl)amino]-1-methylpyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C)C=C1NC(=O)CBr QISBIOBFYGPHSW-UHFFFAOYSA-N 0.000 description 1
- IFUFSZUGLGLZAZ-UHFFFAOYSA-N methyl 4-[(2-bromoacetyl)amino]-2-(2-phenylethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=C(NC(=O)CBr)C=NN1CCC1=CC=CC=C1 IFUFSZUGLGLZAZ-UHFFFAOYSA-N 0.000 description 1
- JJEZCCXZKAPAKD-UHFFFAOYSA-N methyl 4-[(2-bromoacetyl)amino]-2-methylpyrazole-3-carboxylate Chemical compound COC(=O)C1=C(NC(=O)CBr)C=NN1C JJEZCCXZKAPAKD-UHFFFAOYSA-N 0.000 description 1
- GVDHOQWAXBPPRP-UHFFFAOYSA-N methyl 4-amino-1-(1-phenylethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1N)C(C)C1=CC=CC=C1 GVDHOQWAXBPPRP-UHFFFAOYSA-N 0.000 description 1
- ATWPSXSGZQTANJ-UHFFFAOYSA-N methyl 4-amino-1-benzylpyrazole-3-carboxylate Chemical compound C1=C(N)C(C(=O)OC)=NN1CC1=CC=CC=C1 ATWPSXSGZQTANJ-UHFFFAOYSA-N 0.000 description 1
- UBOGPSNFKMAOPP-UHFFFAOYSA-N methyl 4-amino-1-methylpyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C)C=C1N UBOGPSNFKMAOPP-UHFFFAOYSA-N 0.000 description 1
- ACSPAANHVVMRGS-UHFFFAOYSA-N methyl 4-amino-2-(2-phenylethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=C(N)C=NN1CCC1=CC=CC=C1 ACSPAANHVVMRGS-UHFFFAOYSA-N 0.000 description 1
- WMYQZQLKVASMIV-UHFFFAOYSA-N methyl 4-amino-2-methylpyrazole-3-carboxylate Chemical compound COC(=O)C1=C(N)C=NN1C WMYQZQLKVASMIV-UHFFFAOYSA-N 0.000 description 1
- XPCNLFCCXXWHDU-UHFFFAOYSA-N methyl 4-nitro-1-(1-phenylethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C=C1[N+](=O)[O-])C(C)C1=CC=CC=C1 XPCNLFCCXXWHDU-UHFFFAOYSA-N 0.000 description 1
- AQDRRJZTUPUMQN-UHFFFAOYSA-N methyl 4-nitro-2-(2-phenylethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=C([N+]([O-])=O)C=NN1CCC1=CC=CC=C1 AQDRRJZTUPUMQN-UHFFFAOYSA-N 0.000 description 1
- LYKWYELVJJSDPH-UHFFFAOYSA-N methyl 5-[(2-bromoacetyl)amino]-1-methylpyrazole-3-carboxylate Chemical compound COC(=O)C=1C=C(NC(=O)CBr)N(C)N=1 LYKWYELVJJSDPH-UHFFFAOYSA-N 0.000 description 1
- XLULJLJIHOAOHW-UHFFFAOYSA-N methyl 5-[[2-(4-bromophenyl)sulfanylacetyl]amino]-1-methylpyrazole-3-carboxylate Chemical compound CN1N=C(C(=O)OC)C=C1NC(=O)CSC1=CC=C(Br)C=C1 XLULJLJIHOAOHW-UHFFFAOYSA-N 0.000 description 1
- WUIXVASZWOGVEU-UHFFFAOYSA-N methyl 5-amino-1-methylpyrazole-3-carboxylate Chemical compound COC(=O)C=1C=C(N)N(C)N=1 WUIXVASZWOGVEU-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Description
Claims (8)
- 하기 화학식 1로 표시되는 아미노피라졸 유도체 또는 약학적으로 허용가능한 그의 염:[화학식 1]상기 식에서,R2는 -(CH2)2페닐이고;B 는 H 또는 페닐이고;n은 0 또는 1이고;Y는 S, O, CH2, SO, SO2 또는 NH이고;Z는 H, 할로겐, OCH3, NO2, NH2, 또는 C1~C3의 직쇄 또는 측쇄 알킬이고;
- 제 1 항에 있어서,하기 화합물로 구성된 군으로부터 선택된 것임을 특징으로 하는, 아미노피라졸 유도체 또는 약학적으로 허용가능한 그의 염:4-[2-(4-브로모-페닐설판일)-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산 메틸 에스터;4-[2-(페닐설판일)-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산 메틸 에스터;4-[2-(3-메톡시-페닐설판일)-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산 메틸 에스터;4-[2-(4-니트로-페닐설판일)-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산 메틸 에스터;4-[2-(2-아미노-페닐설판일)-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산 메틸 에스터;4-[2-(4-메틸-페닐설판일)-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산 메틸 에스터;4-[2-(4-플루오로-페닐설판일)-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산 메틸 에스터;4-[2-(2-피리딜설판일)-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산 메틸 에스터;4-[2-(2-피리딜설핀일)-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산 메틸 에스터;4-[2-(2-피리딜설폰일)-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산 메틸 에스터;4-[2-(3,4-디메틸-페닐설판일)-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산 메틸 에스터;4-[2-(4-브로모-페닐설판일)-아세틸아미노]-2-펜에틸-2H-피라졸-3-카복실산 메틸 에스터;4-[3-(4-브로모-페닐설판일)-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산 메틸 에스터;5-[2-(4-브로모-페닐설판일)-아세틸아미노]-1-펜에틸-1H-피라졸-4-카복실산 에틸 에스터;4-[2-(4-브로모-페닐설판일)-2-페닐-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산 메틸 에스터;4-[2-(4-브로모-페닐설판일)-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산;2-(4-브로모-페닐설판일)-N-[3-(4,5-디하이드로-옥사졸-2-일)-1-펜에틸-1H-피라졸-4-닐]-아세타미드;4-[2-(4-브로모-페닐설판일)-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산 아미드;2-(4-브로모-페닐설판일)-N-(3-하이드록시메틸-1-펜에틸-1H-피라졸-4-일)-아세타미드;4-[3-페닐-프로피오닐아미노]-1-펜에틸-1H-피라졸-3-카복실산 메틸 에스터;4-[2-(4-브로모-페녹시)-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산 메틸 에스터;4-[2-(4-브로모-페닐아미노)-아세틸아미노]-1-펜에틸-1H-피라졸-3-카복실산 메틸 에스터; 및2-(4-브로모-페닐설판일)-N-(3-메톡시메틸-1-펜에틸-1H-피라졸-4-일)-아세타미드.
- 제 1 항의 아미노피라졸 유도체 또는 약학적으로 허용되는 그의 염을 유효성분으로 함유하는 허혈성 질환의 예방 또는 치료용 조성물.
- 제 5 항에 있어서,허혈성 질환이 허혈성 세포사에 의해 매개되는 뇌허혈, 심장허혈, 당뇨병성 혈관심장질환, 심부전, 심근비대증, 망막허혈, 허혈성 대장염, 허혈성 급성 신부전증, 뇌졸중, 뇌외상, 알츠하이머 병, 파킨슨 병, 신생아 저산소증, 녹내장 및 당뇨성 신경증으로 이루어진 군으로부터 선택되는 것임을 특징으로 하는 조성물.
- 제 6 항에 있어서, 허혈성 세포사가 저산소 조건에 의해 유도되는 것임을 특징으로 하는 조성물.
- 제 1 항의 아미노피라졸 유도체 또는 약학적으로 허용가능한 그의 염을 유효성분으로 함유하는 장기 보호용 조성물.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060105183A KR100832747B1 (ko) | 2006-10-27 | 2006-10-27 | 아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물 |
PCT/KR2007/005311 WO2008051047A1 (en) | 2006-10-27 | 2007-10-26 | Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same |
CN2007800401170A CN101528687B (zh) | 2006-10-27 | 2007-10-26 | 氨基吡唑衍生物、其制备方法以及含有其的用于预防或治疗缺血性疾病的组合物 |
PL07833620T PL2059503T3 (pl) | 2006-10-27 | 2007-10-26 | Pochodne aminopirazolu, sposób ich wytwarzania oraz kompozycja do zapobiegania lub leczenia chorób niedokrwiennych zawierająca takie pochodne |
JP2009534498A JP5096476B2 (ja) | 2006-10-27 | 2007-10-26 | アミノピラゾール誘導体、その製造方法、およびそれを含有する虚血性疾患の予防または治療用組成物 |
AU2007309854A AU2007309854B2 (en) | 2006-10-27 | 2007-10-26 | Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same |
CA2666975A CA2666975C (en) | 2006-10-27 | 2007-10-26 | Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same |
EP07833620.3A EP2059503B1 (en) | 2006-10-27 | 2007-10-26 | Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same |
US12/447,394 US7939550B2 (en) | 2006-10-27 | 2007-10-26 | Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same |
ES07833620.3T ES2546183T3 (es) | 2006-10-27 | 2007-10-26 | Derivados de aminopirazol, su procedimiento para la preparación, y composición para utilización en la prevención o tratamiento de enfermedades isquémicas que contiene dichos derivados |
DK07833620.3T DK2059503T3 (en) | 2006-10-27 | 2007-10-26 | Aminopyrazole derivatives, processes for their preparation, and compositions containing these derivatives for the prevention or treatment of ischemic diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060105183A KR100832747B1 (ko) | 2006-10-27 | 2006-10-27 | 아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080037911A KR20080037911A (ko) | 2008-05-02 |
KR100832747B1 true KR100832747B1 (ko) | 2008-05-27 |
Family
ID=39324788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060105183A KR100832747B1 (ko) | 2006-10-27 | 2006-10-27 | 아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물 |
Country Status (11)
Country | Link |
---|---|
US (1) | US7939550B2 (ko) |
EP (1) | EP2059503B1 (ko) |
JP (1) | JP5096476B2 (ko) |
KR (1) | KR100832747B1 (ko) |
CN (1) | CN101528687B (ko) |
AU (1) | AU2007309854B2 (ko) |
CA (1) | CA2666975C (ko) |
DK (1) | DK2059503T3 (ko) |
ES (1) | ES2546183T3 (ko) |
PL (1) | PL2059503T3 (ko) |
WO (1) | WO2008051047A1 (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101600683B (zh) | 2006-07-05 | 2013-06-12 | 法博太科制药有限公司 | 治疗性化合物 |
WO2009079692A1 (en) | 2007-12-21 | 2009-07-02 | Fibrotech Therapeutics Pty Ltd | Halogenated analogues of anti-fibrotic agents |
US9062076B2 (en) | 2009-10-22 | 2015-06-23 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
JP2017521464A (ja) * | 2014-07-24 | 2017-08-03 | バイエル・ファルマ・アクティエンゲゼルシャフト | グルコース輸送阻害剤 |
ITUB20159668A1 (it) * | 2015-12-29 | 2017-06-29 | Univ Degli Studi Di Modena E Reggio Emilia | Farmaci antitumorali |
MX2019009235A (es) | 2017-02-03 | 2019-12-11 | Certa Therapeutics Pty Ltd | Compuestos antifibroticos. |
MX2019015273A (es) * | 2017-06-19 | 2020-08-17 | Kainos Medicine Inc | Moduladores de alfa-sinucleinca. |
AU2019214959B2 (en) * | 2018-01-30 | 2023-05-11 | Kainos Medicine Inc. | Salt forms of organic compound |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072576A1 (en) * | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
WO2005051919A1 (en) * | 2003-11-26 | 2005-06-09 | Pfizer Products Inc. | Aminopyrazole derivatives as gsk-3 inhibitors |
US20050209297A1 (en) * | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
WO2006085685A1 (ja) * | 2005-02-09 | 2006-08-17 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1651612T3 (pl) * | 2003-07-22 | 2012-09-28 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
GB0328796D0 (en) | 2003-12-12 | 2004-01-14 | Biofocus Plc | Compounds which interact with the G-protein coupled receptor family |
US20060063930A1 (en) | 2004-08-20 | 2006-03-23 | Agoston Gregory E | Compositions and methods comprising proteinase activated receptor antagonists |
-
2006
- 2006-10-27 KR KR1020060105183A patent/KR100832747B1/ko active IP Right Grant
-
2007
- 2007-10-26 CA CA2666975A patent/CA2666975C/en active Active
- 2007-10-26 ES ES07833620.3T patent/ES2546183T3/es active Active
- 2007-10-26 WO PCT/KR2007/005311 patent/WO2008051047A1/en active Application Filing
- 2007-10-26 CN CN2007800401170A patent/CN101528687B/zh active Active
- 2007-10-26 JP JP2009534498A patent/JP5096476B2/ja active Active
- 2007-10-26 AU AU2007309854A patent/AU2007309854B2/en active Active
- 2007-10-26 PL PL07833620T patent/PL2059503T3/pl unknown
- 2007-10-26 US US12/447,394 patent/US7939550B2/en active Active
- 2007-10-26 DK DK07833620.3T patent/DK2059503T3/en active
- 2007-10-26 EP EP07833620.3A patent/EP2059503B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050209297A1 (en) * | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
WO2002072576A1 (en) * | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
WO2005051919A1 (en) * | 2003-11-26 | 2005-06-09 | Pfizer Products Inc. | Aminopyrazole derivatives as gsk-3 inhibitors |
WO2006085685A1 (ja) * | 2005-02-09 | 2006-08-17 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
Also Published As
Publication number | Publication date |
---|---|
CN101528687A (zh) | 2009-09-09 |
AU2007309854B2 (en) | 2011-04-28 |
EP2059503B1 (en) | 2015-08-26 |
CA2666975C (en) | 2011-11-15 |
WO2008051047A1 (en) | 2008-05-02 |
JP5096476B2 (ja) | 2012-12-12 |
KR20080037911A (ko) | 2008-05-02 |
US20100063106A1 (en) | 2010-03-11 |
PL2059503T3 (pl) | 2016-01-29 |
DK2059503T3 (en) | 2015-12-07 |
CA2666975A1 (en) | 2008-05-02 |
EP2059503A1 (en) | 2009-05-20 |
EP2059503A4 (en) | 2014-07-30 |
US7939550B2 (en) | 2011-05-10 |
AU2007309854A1 (en) | 2008-05-02 |
JP2010507653A (ja) | 2010-03-11 |
CN101528687B (zh) | 2012-03-14 |
ES2546183T3 (es) | 2015-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100832747B1 (ko) | 아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물 | |
JP6861858B2 (ja) | Ssao阻害剤 | |
AU2020260400B2 (en) | Human plasma kallikrein inhibitors | |
KR100739359B1 (ko) | 디아제판 유도체 또는 이의 염 | |
WO1999019303A1 (fr) | Derives de pyrazole | |
OA12444A (fr) | Indanylamines acylées et leur utilisation en tant que produit pharmaceutique. | |
SA04250299B1 (ar) | مشتقات 2- بيريدون تعمل كمثبطات لانزيم ايلاستيز النتروفيل واستخدامها | |
JP2008530074A (ja) | Hm74a受容体アゴニストとしてのアントラニル酸誘導体 | |
JP2005519953A (ja) | 環状アミド類 | |
EP2673263A1 (en) | Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators | |
CA3095451C (en) | Ox2r compounds | |
WO2012038904A1 (fr) | Derives de nicotinamide, leur preparation et leur application en therapeutique | |
JP5149794B2 (ja) | 飽和リンカー基を含有するヘテロアリール置換アミドおよび医薬としてのその使用 | |
JP2000053649A (ja) | スルホニルウレイドピラゾール誘導体 | |
KR100937134B1 (ko) | 아마이드로 치환된 벤조퓨란 및 벤조싸이오펜 유도체, 이의제조 방법 및 이를 포함하는 약학적 조성물 | |
KR100860539B1 (ko) | 아미노싸이오펜 유도체를 함유하는 허혈성 질환의 예방또는 치료용 조성물 | |
KR20060021896A (ko) | 세로토닌 재흡수 저해제 형태의 인돌 유도체 | |
KR100832750B1 (ko) | N-페닐아마이드 유도체를 함유하는 허혈성 질환의 예방또는 치료용 조성물 | |
KR100832751B1 (ko) | N-페닐아마이드 유도체 및 이의 제조방법 | |
US20040077878A1 (en) | Process for the preparation of tri-nitrogen containing heteroaryl-diamine derivatives useful as pharmaceutical agents and methods of producing pharmaceutical agents | |
WO2008069611A1 (en) | N-phenylamide derivative, process for the preparation thereof, and composition for preventing or treating ischemic diseases comprising same | |
JP6078153B2 (ja) | チアンジンアミド誘導体、並びにその医薬組成物及び使用 | |
TW202235408A (zh) | 化合物 | |
KR20050098889A (ko) | 벤조퓨란 유도체 및 항우울제 및 불안완화제로서의 이의용도 | |
JPH06228100A (ja) | 光学活性アミノピリジン誘導体およびその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120305 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20130329 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150420 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160405 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170518 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180409 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190508 Year of fee payment: 12 |